Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study.
ImmTAC
T cell engager
overall survival
real-life data
tebentafusp
uveal melanoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Jun 2023
30 Jun 2023
Historique:
received:
12
05
2023
revised:
16
06
2023
accepted:
28
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting. This retrospective, multicenter study analyzed the outcomes and safety of tebentafusp therapy in 78 patients with mUM. Patients treated with tebentafusp had a median PFS of 3 months (95% CI 2.7 to 3.3) and a median OS of 22 months (95% CI 10.6 to 33.4). In contrast to a published Phase 3 study, our cohort had a higher rate of patients with elevated LDH (65.4% vs. 35.7%) and included patients with prior systemic and local ablative therapies. In patients treated with tebentafusp following ICI, there was a trend for a longer median OS (28 months, 95% CI 26.9 to 29.1) compared to the inverse treatment sequence (24 months, 95% CI 13.0 to 35.0, Data from this real-life cohort showed a median PFS/OS similar to published Phase 3 trial data. Treatment with ICI followed by tebentafusp may result in longer PFS/OS compared to the inverse treatment sequence.
Sections du résumé
BACKGROUND
BACKGROUND
Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting.
PATIENTS AND METHODS
METHODS
This retrospective, multicenter study analyzed the outcomes and safety of tebentafusp therapy in 78 patients with mUM.
RESULTS
RESULTS
Patients treated with tebentafusp had a median PFS of 3 months (95% CI 2.7 to 3.3) and a median OS of 22 months (95% CI 10.6 to 33.4). In contrast to a published Phase 3 study, our cohort had a higher rate of patients with elevated LDH (65.4% vs. 35.7%) and included patients with prior systemic and local ablative therapies. In patients treated with tebentafusp following ICI, there was a trend for a longer median OS (28 months, 95% CI 26.9 to 29.1) compared to the inverse treatment sequence (24 months, 95% CI 13.0 to 35.0,
CONCLUSIONS
CONCLUSIONS
Data from this real-life cohort showed a median PFS/OS similar to published Phase 3 trial data. Treatment with ICI followed by tebentafusp may result in longer PFS/OS compared to the inverse treatment sequence.
Identifiants
pubmed: 37444540
pii: cancers15133430
doi: 10.3390/cancers15133430
pmc: PMC10341126
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : This work was supported by the German Federal Ministry of Education and Research (BMBF) as part of the project emed:MelAutim
ID : 01ZX1905E
Références
J Immunother Cancer. 2020 Dec;8(2):
pubmed: 33262254
Arch Ophthalmol. 2005 Dec;123(12):1639-43
pubmed: 16344433
Arch Ophthalmol. 2009 Aug;127(8):989-98
pubmed: 19667335
Cancers (Basel). 2021 Dec 20;13(24):
pubmed: 34945010
Oncotarget. 2018 Jun 22;9(48):28903-28909
pubmed: 29988983
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Cancers (Basel). 2023 Apr 28;15(9):
pubmed: 37174003
Front Oncol. 2021 Apr 13;11:642466
pubmed: 33928030
Surg Oncol Clin N Am. 2021 Jan;30(1):103-123
pubmed: 33220800
Cancer Res. 1992 Dec 1;52(23):6561-6
pubmed: 1423301
Cancer Treat Rev. 2023 Apr;115:102543
pubmed: 36931146
Jpn J Ophthalmol. 2019 Mar;63(2):197-209
pubmed: 30796549
J Clin Oncol. 2021 Feb 20;39(6):586-598
pubmed: 33417511
Leukemia. 2021 Aug;35(8):2220-2231
pubmed: 33542479
Indian J Ophthalmol. 2015 Feb;63(2):93-102
pubmed: 25827538
Nat Rev Clin Oncol. 2020 Jul;17(7):418-434
pubmed: 32242094
J Clin Oncol. 2022 Jan 10;40(2):127-137
pubmed: 34818112
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
N Engl J Med. 2021 Sep 23;385(13):1196-1206
pubmed: 34551229
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
Nat Med. 2022 Nov;28(11):2364-2373
pubmed: 36229663
Nature. 2020 Mar;579(7798):274-278
pubmed: 32103181
J Clin Oncol. 2021 Feb 20;39(6):599-607
pubmed: 33125309